A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

This study is testing a modified CAR-T cell therapy called 19-28z/IL-18 in patients with B-cell acute lymphoblastic leukemia (ALL) — a blood cancer — that has returned or did not respond to previous treatments. **You may be eligible if...** - You have B-cell ALL that has relapsed or not responded to at least one prior chemotherapy regimen - If you have Philadelphia chromosome-positive ALL, your disease has persisted despite at least one newer targeted therapy (TKI) - The first patients enrolled must be 17 or older; later patients may be 12 or older **You may NOT be eligible if...** - Your leukemia does not have the CD19 marker that the therapy targets - Your organ function does not meet minimum health requirements - You have active serious infections or serious autoimmune conditions Talk to your doctor to see if this trial is right for you.